

e-Table 1. Drug classification

Category Name	Generic Name
Antiplatelets	clopidogrel, cilostazol, ticlopidine <sup>2</sup> , beraprost, beraprost–long acting, complavin
Anticoagulants <sup>2,3</sup>	dabigatran
Statins <sup>1,2,3</sup>	atorvastatin <sup>2</sup> , simvastatin, pitavastatin, fluvastatin, pravastatin, rosuvastatin, amlodipine/atorvastatin
Sodium channel blockers <sup>4,5†</sup>	mexiletine, aprindine, cibenzoline
Beta blocker	acebutolol <sup>2</sup>
Class III antiarrhythmic drugs	amiodarone <sup>1–6</sup>
Calcium channel blockers	bepridil <sup>1</sup> , amlodipine/atorvastatin, telmisartan/amlodipine, valsartan/amlodipine, valsartan/cilnidipine, candesartan/amlodipine
Angiotensin/convertng enzyme inhibitor <sup>2‡</sup>	enalapril
Thiazides	trichlormethiazide, hydrochlorothiazide <sup>3,5</sup> , benzyhydrochlorothiazide/reserpine/carbazochrome, mefruside, telmisartan/hydrochlorothiazide, valsartan/hydrochlorothiazide, candesartan/hydrochlorothiazide, candesartan/trichlormethiazide, losartan/hydrochlorothiazide
NSAIDs	diclofenac <sup>2</sup> , celecoxib, loxoprofen, etodolac, nabumetone, pranoprofen
Anti-rheumatics	actarit, iguratimod, tofacitinib, penicillamine <sup>2–5</sup> , leflunomide <sup>1,3</sup> , sodium aurothiomalate <sup>2–6#</sup> , bucillamine
Leukotriene receptor antagonist <sup>2*</sup>	pranlukast
5-ASA	mesalazine, salazosulfapyridine <sup>5</sup>
Tricyclic antidepressant	Imipramine <sup>5</sup> , cromipramine, maprotiline
Antiepileptics	valproate, phenytoin <sup>2,3,5</sup> , ethotoin, carbamazepine <sup>2–5</sup> , zonisamide
Interferon <sup>1,2,3</sup>	interferon/alpha/2b, interferon/alpha, interferon/beta/1a, interferon/beta, interferon/gamma/1a, PEG/interferon/alpha/2a, PEG/interferon/alpha/2b
Immunoglobulin <sup>6</sup>	thymoglobuline, zetbulin
Sulfamethoxazole/trimethoprim	sulfamethoxazole/trimethoprim <sup>2</sup>
Quinolones	levofloxacin, garenoxacin, moxifloxacin, pazufloxacin, tosufloxacin, sitafloxacin, ofloxacin, ciprofloxacin <sup>2</sup> , norfloxacin, prulifloxacin, lomefloxacin
Tetracyclines	minocycline <sup>2,3</sup>
Beta-lactams	penicillin <sup>2,5</sup> (augmentin, amoxicillin, sultamicillin, piperacillin/tazobactam, piperacillin); cephalosporin <sup>2</sup> (cefoperazone/sulbactam, cefaclor, cefazolin, cefalexin, cefalotin, cefixime, cefepime, ceftazidime, cefotaxime, cefotiam, cefoperazone, cefcapene, ceftidoren, cefdinir, ceftazidime, ceftizoxime, ceftibuten, cefteteram, ceftriaxone, cefpirome, cefpodoxime, cefminox, cefmetazole, cefmenoxime, cefroxadine, cefuroxime, flomoxef, latamoxef); penem (imipenem/cilastatin, tebipenem, doripenem, panipenem/betamipron, biapenem, faropenem, meropenem)
Anti-tuberculosis drugs	streptomycin, rifampicin <sup>2</sup> , isonicotinyl hydrazide methanesulfonate, isoniazid <sup>2,3,5</sup> , ethambutol
EGFR inhibitors	afatinib, erlotinib <sup>1,3</sup> , gefitinib <sup>1–3,6</sup>
Molecular targeted drugs	imatinib <sup>1,3</sup> , sunitinib <sup>6</sup> , sorafenib, vandetanib, pazopanib, bortezomib, lapatinib
Anti PD-1 antibody	nivolumab <sup>1</sup>
Anti CTLA4 antibody	ipilimumab <sup>1</sup>
mTOR inhibitor <sup>1</sup>	everolimus

Platinum	oxaliplatin <sup>6</sup> , carboplatin <sup>6</sup> , cisplatin <sup>6</sup> , nedaplatin, miliplatin
Topoisomerases	irinotecan <sup>1,6</sup> , nogitecan, etoposide <sup>3,6</sup> , sobuzoxane
Pyrimidine	capecitabine, gemcitabine <sup>1-3,6</sup> , cytarabine ocfosfate, cytarabine <sup>2,3,6</sup> , tegafur/gimeracil/oteracil, 5-fluorouracil <sup>4,6</sup> , trifluridine, doxifluridine
Anthracyclines	amrubicin, epirubicin, adriamycin <sup>4</sup> , doxorubicin <sup>2,3,6</sup> , pirarubicin, mitoxantrone
Biological products	infliximab <sup>2,3,6</sup> , adalimumab <sup>2,3</sup> , abatacept, ustekinumab, etanercept, golimumab, certolizumab, ofatumumab, gemtuzumab, trastuzumab <sup>3</sup> , trastuzumab emtansine, panitumumab <sup>1</sup> , bevacizumab <sup>3</sup> , mogamulizumab, rituximab <sup>1,3,6</sup> , tocilizumab <sup>1</sup>
Microtubule polymerisation inhibitors	eribulin, vinblastine <sup>2-4,6</sup> , docetaxel <sup>1,3,6</sup> , nab-paclitaxel, paclitaxel <sup>2,3,6</sup> , vinorelbine <sup>6</sup> , vindesine <sup>4,6</sup>
Purine metabolism antagonists	azathioprine <sup>3,4,6</sup> , mizoribine, cladribine, fludarabine <sup>3,6</sup>
Folic acid antagonists	methotrexate <sup>1-6</sup> , pemetrexed <sup>1</sup>
DNA synthesis inhibitors	bleomycin <sup>1-6</sup> , peplomycin, mitomycin <sup>2-4,6</sup>
Hormone therapy drugs	goserelin, degarelix, leuprorelin <sup>6</sup> , danazol, bicalutamide, flutamide <sup>3</sup> , anastrozole, tamoxifen
Alkylators	ifosfamide, cyclophosphamide <sup>1-4,6</sup> , temozolomide, nimustine, busulfan <sup>3,4,6</sup> , procarbazine <sup>3,4,5</sup> , bendamustine, melphalan <sup>3,4,6</sup> , ranimustine
Cytokine <sup>6**</sup>	celmoleukin
Thalidomide	thalidomide <sup>3</sup>
Retinoid	tretinoin <sup>2,6</sup>
BCG <sup>3</sup>	immucyst

NSAIDs: non-steroidal anti-inflammatory drugs; 5-ASA: 5-aminosalicylic acid; G-CSF: granulocyte-colony stimulating factor; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; PD-1: programmed cell death 1; CTLA4: cytotoxic T-lymphocyte-associated antigen 4; DNA: deoxyribonucleic acid; BCG: Bacille Calmette Guerin

†, referred to lidocaine; ‡, referred to captopril; #, referred to as gold or gold salts; \*, referred to zafirleukast; \*\*, referred to IL-2 and Tumor necrosis factor

1. Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug-Induced Interstitial Lung Disease: A Systematic Review. *J Clin Med*. 2018; 7. doi: 10.3390/jcm7100356.
2. Prasad R, Gupta P, Singh A, Goel N. Drug induced pulmonary parenchymal disease. *Drug Discov Ther*. 2014;8(6):232-7.
3. Schwaiblmair M, Behr W, Haeckel T, Markl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. *Open Respir Med J* 2012; 6: 63-74.
4. Cooper JA, Jr., White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. *Am Rev Respir Dis*. 1986; 133: 321-40.
5. Cooper JA, Jr., White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs. *Am Rev Respir Dis*. 1986; 133: 488-505.
6. Dhokarh R, Li G, Schmickl CN, Kashyap R, Assudani J, Limper AH, Gajic O. Drug-associated acute lung injury: a population-based cohort study. *Chest* 2012; 142: 845-850.

e-Tables 2. Population of patients prescribed drugs with potential risk during hospitalisation

Drug category with potential risk	Prescribed during hospitalisation				Prescribed before corticosteroids during hospitalisation			
	Cases		Controls		Cases		Controls	
	(n = 1,541)		(n = 5,677)		(n = 1,541)		(n = 5,677)	
	n	%	n	%	n	%	n	%
Antiplatelets	111	7.2	353	6.2	44	2.9	150	2.6
Anticoagulants	14	0.9	34	0.6	7	0.5	11	0.2
Statins	200	13	763	13	60	3.9	294	5.2
Sodium channel blockers	27	1.8	67	1.2	10	0.6	30	0.5
Beta blocker	0	0	1	0.01	0	0	1	0.02
Class III antiarrhythmic drugs	70	4.5	72	1.3	45	2.9	36	0.6
Calcium channel blockers	19	1.2	49	0.9	5	0.3	17	0.3
Angiotensin/converting enzyme inhibitor	46	3.0	173	3.0	16	1.0	73	1.3
Thiazides	43	2.8	159	2.8	11	0.7	67	1.2
NSAIDs	791	51	2159	38	360	23	952	17
Anti-rheumatics	5	0.3	27	0.5	1	0.06	6	0.1
Leukotriene receptor antagonist	5	0.3	33	0.6	0	0	6	0.1
5-ASA	20	1.2	47	0.8	3	0.2	10	0.2
Tricyclic antidepressant	5	0.3	16	0.3	1	0.06	8	0.1
Antiepileptics	42	2.7	170	3.0	16	1.0	53	0.9
Interferon	2	0.1	12	0.2	2	0.1	8	0.1
Immunoglobulin	1	0.1	1	0.02	0	0	0	0
Sulfamethoxazole/trimethoprim	921	60	433	7.6	30	1.9	47	0.8
Quinolones	662	43	1106	19	175	11	246	4.3
Tetracyclines	117	7.6	167	2.9	41	2.7	71	1.3
Beta-lactams	1274	83	3460	61	639	41	1942	34
Anti-tuberculosis drugs	53	3.4	67	1.2	14	0.9	28	0.5
EGFR inhibitors	109	7.1	226	4.0	76	4.9	109	1.9
Molecular targeted drugs	23	1.5	55	1.0	3	0.2	7	0.1
Anti PD-1 antibody	1	0.06	2	0.03	1	0.06	1	0.02
Anti CTLA4 antibody	0	0	0	0	0	0	0	0
mTOR inhibitor	3	0.2	7	0.1	2	0.1	5	0.09
Platinum	114	7.4	663	12	4	0.3	11	0.2
Topoisomerases	51	3.3	221	3.9	3	0.2	5	0.09
Pyrimidine	121	7.9	338	6.0	16	1.0	54	1.0
Anthracyclines	51	3.3	132	2.3	9	0.6	12	0.2
Biological products	45	2.9	198	3.5	3	0.2	5	
Microtubule polymerisation inhibitors	147	9.5	378	6.7	4	0.3	11	0.09
Purine metabolism antagonists	6	0.4	21	0.4	0	0	2	0.04
Folic acid antagonists	59	3.8	249	4.4	3	0.2	4	0.07
DNA synthesis inhibitors	4	0.3	5	0.09	1	0.06	3	0.05
Hormone therapy drugs	18	1.2	34	0.6	8	0.5	10	0.17
Alkylators	69	4.5	118	2.1	0	0	4	0.07
Cytokine	0	0	0	0	0	0	0	0
Thalidomide	1	0.06	5	0.09	0	0	1	0.02
Retinoid	0	0	2	0.04	0	0	0	0

---

BCG	1	0.06	0	0	0	0	0	0
-----	---	------	---	---	---	---	---	---

---

NSAIDs: non-steroidal anti-inflammatory drugs; 5-ASA: 5-aminosalicylic acid; EGFR: epidermal growth factor receptor; PD-1: programmed cell death 1; CTLA4: cytotoxic T-lymphocyte-associated antigen 4; DNA: deoxyribonucleic acid; BCG: Bacille Calmette Guerin